Literature DB >> 10805332

An association between migraine and cutaneous allodynia.

R Burstein1, D Yarnitsky, I Goor-Aryeh, B J Ransil, Z H Bajwa.   

Abstract

Recent animal studies on the mechanism of migraine show that intracranial pain is accompanied by increased periorbital skin sensitivity. These findings suggest that the pathophysiology of migraine involves not only irritation of meningeal perivascular pain fibers but also a transient increase in the responsiveness (ie, sensitization) of central pain neurons that process information arising from intracranial structures and skin. The purpose of this study was to determine whether the increased skin sensitivity observed in animal also develops in humans during migraine attacks. Repeated measurements of mechanical and thermal pain thresholds of periorbital and forearm skin areas in the absence of, and during, migraine attacks enabled us to determine the occurrence of cutaneous allodynia during migraine. Cutaneous allodynia is pain resulting from a nonnoxious stimulus to normal skin. In 79% of the patients, migraine was associated with cutaneous allodynia as defined, and in 21% of the patients it was not. The cutaneous allodynia occurred either solely within the referred pain area on the ipsilateral head, or within and outside the ipsilateral head. Cutaneous allodynia in certain well-defined regions of the skin during migraine is an as yet unreported neurological finding that points to hyperexcitability of a specific central pain pathway that subserves intracranial sensation.

Entities:  

Mesh:

Year:  2000        PMID: 10805332

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  261 in total

1.  Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP.

Authors:  Henrik Winther Schytz; Helle Holst; Lars Arendt-Nielsen; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2010-05-09       Impact factor: 7.277

2.  The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.

Authors:  Valérie Kayser; Bertrand Aubel; Michel Hamon; Sylvie Bourgoin
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine.

Authors:  Caterina Mainero; Jasmine Boshyan; Nouchine Hadjikhani
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

4.  Episodic and chronic migraineurs are hypersensitive to thermal stimuli between migraine attacks.

Authors:  Todd J Schwedt; Melissa J Krauss; Karen Frey; Robert W Gereau
Journal:  Cephalalgia       Date:  2010-04-07       Impact factor: 6.292

Review 5.  Update on medication-overuse headache.

Authors:  Milena De Felice; Michael H Ossipov; Frank Porreca
Journal:  Curr Pain Headache Rep       Date:  2011-02

Review 6.  Migraine headache: options for acute treatment.

Authors:  Frederick R Taylor
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

7.  Chronic Daily Headache.

Authors:  James R. Couch
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

8.  In child and adult migraineurs the somatosensory cortex stands out … again: An arterial spin labeling investigation.

Authors:  Andrew M Youssef; Allison Ludwick; Sophie L Wilcox; Alyssa Lebel; Ke Peng; Elisabeth Colon; Amy Danehy; Rami Burstein; Lino Becerra; David Borsook
Journal:  Hum Brain Mapp       Date:  2017-05-31       Impact factor: 5.038

Review 9.  Central sensitisation and cutaneous allodynia in migraine: implications for treatment.

Authors:  Stephen Landy; Kathryn Rice; Bob Lobo
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Startle reactivity in children at risk for migraine.

Authors:  Roman Duncko; Lihong Cui; Jeffrey Hille; Christian Grillon; Kathleen R Merikangas
Journal:  Clin Neurophysiol       Date:  2008-10-31       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.